Nucl Med Mol Imaging.  2019 Aug;53(4):247-252. 10.1007/s13139-019-00601-1.

Treatment Response Assessment of Skeletal Metastases in Prostate Cancer with ¹⁸F-NaF PET/CT

• Velez EM
• Desai B
• Jadvar H

• KMID: 2455519
• DOI: http://doi.org/10.1007/s13139-019-00601-1

Abstract

PURPOSE
To determine the utility of ¹â¸F-sodium fluoride positron emission tomography-computed tomography (¹â¸F-NaF PET/CT) in the imaging assessment of therapy response in men with osseous-only metastatic prostate cancer.
METHODS
In this Institutional Review Board-approved single institution retrospective investigation, we evaluated 21 ¹â¸F-NaF PET/CTscans performed in 14 patients with osseous metastatic disease from prostate cancer and no evidence of locally recurrent or soft-tissue metastatic disease who received chemohormonal therapy. Imaging-based qualitative and semi-quantitative parameters were defined and compared with changes in serum PSA level.
RESULTS
Qualitative and semi-quantitative image-based assessments demonstrated > 80% concordance with good correlation (SUV(max) κ = 0.71, SUVavg κ = 0.62, SUVsum κ = 0.62). Moderate correlation (κ = 0.43) was found between SUV(max) and PSA-based treatment response assessments. There was no statistically significant correlation between PSA-based disease progression and semi-quantitative parameters. Qualitative imaging assessment was moderately correlated (κ = 0.52) with PSA in distinguishing responders and non-responders.
CONCLUSION
¹â¸F-NaF PET/CT is complementary to biochemical monitoring in patients with bone-only metastases from prostate cancer which can be helpful in subsequent treatment management decisions.

Keyword

¹⁸F-NaF; PET/CT; Prostate; Cancer; Metastasis; Bone

MeSH Terms

Disease Progression
Electrons
Fluorides
Humans
Male
Neoplasm Metastasis*
Positron-Emission Tomography and Computed Tomography*
Prostate*
Prostatic Neoplasms*
Retrospective Studies
Fluorides